<DOC>
	<DOC>NCT00595374</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to compare the efficacy and safety of insulin detemir and insulin NPH in adults with type 1 diabetes on blood glucose control.</brief_summary>
	<brief_title>Efficacy and Safety of Insulin Detemir in Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Isophane insulin, beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<mesh_term>Isophane Insulin, Human</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Duration of type 1 diabetes for at least 12 months BMI below 35 kg/m2 HbA1c between 7.012.0% Current treatment with preprandial short acting insulin and insulin NPH once or twice daily for at least 6 months Fertile females must use acceptable method of contraception if there is any risk of pregnancy in the opinion of the Investigator Known or suspected allergy to trial product or related products Previous participation in this trial Receipt of any investigational products within the last 2 months prior to this trial Drug or alcohol dependence Pregnancy, breastfeeding or intention of becoming pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>